Mad Girl Investor
07-01-2006, 03:09 PM
Look at the chart, a break out has begun, PR coming July 5th. 4 Million volume yesterday. 62 million float. A traders dream.
Dear Fellow Shareholder:
First Quarter 2006 Financial Results/Stock Performance
The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.
Recently, an industry source published information regarding each of the public companies competing in the stem cell arena. Of the sixteen companies listed, CalbaTech was listed third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization), and first in average daily trading volume, yet had the second lowest market capitalization. We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach our pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service set to open in June, the price of our stock should respond accordingly.
We have put the building blocks in place and have begun building a truly successful company. We are pleased that you have chosen to invest in CalbaTech. Thank you for the trust and continued support.
Sincerely,
James DeOlden
Chief Executive Officer
Dear Fellow Shareholder:
First Quarter 2006 Financial Results/Stock Performance
The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.
Recently, an industry source published information regarding each of the public companies competing in the stem cell arena. Of the sixteen companies listed, CalbaTech was listed third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization), and first in average daily trading volume, yet had the second lowest market capitalization. We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach our pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service set to open in June, the price of our stock should respond accordingly.
We have put the building blocks in place and have begun building a truly successful company. We are pleased that you have chosen to invest in CalbaTech. Thank you for the trust and continued support.
Sincerely,
James DeOlden
Chief Executive Officer